IFM Investors Pty Ltd Has $7.63 Million Stock Holdings in Axon Enterprise, Inc $AXON

IFM Investors Pty Ltd raised its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 1.3% in the 1st quarter, Holdings Channel.com reports. The fund owned 14,501 shares of the biotechnology company’s stock after buying an additional 185 shares during the quarter. IFM Investors Pty Ltd’s holdings in Axon Enterprise were worth $7,627,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXON. GAMMA Investing LLC raised its holdings in Axon Enterprise by 58,725.5% in the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company’s stock valued at $402,210,000 after acquiring an additional 763,431 shares in the last quarter. Jennison Associates LLC raised its holdings in Axon Enterprise by 23,203.7% in the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after acquiring an additional 611,418 shares in the last quarter. Nuveen LLC acquired a new position in Axon Enterprise in the 1st quarter valued at $264,796,000. Westfield Capital Management Co. LP raised its holdings in Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after acquiring an additional 212,931 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock valued at $4,540,005,000 after acquiring an additional 185,571 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Northland Securities set a $800.00 target price on Axon Enterprise in a report on Tuesday, August 5th. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the company an “overweight” rating in a research report on Friday, July 11th. JPMorgan Chase & Co. lifted their target price on Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research report on Thursday, July 17th. Wolfe Research initiated coverage on Axon Enterprise in a research report on Monday, July 7th. They issued an “outperform” rating on the stock. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $855.00 target price (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $837.69.

Axon Enterprise Stock Up 2.1%

Shares of NASDAQ:AXON opened at $747.55 on Thursday. The company has a fifty day moving average of $762.78 and a 200-day moving average of $682.93. The company has a market capitalization of $58.68 billion, a PE ratio of 184.58, a price-to-earnings-growth ratio of 26.87 and a beta of 1.40. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a 52-week low of $353.91 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.58. The company had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company’s revenue for the quarter was up 32.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Activity at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 75 shares of the company’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $723.50, for a total transaction of $54,262.50. Following the completion of the transaction, the chief accounting officer directly owned 15,080 shares in the company, valued at approximately $10,910,380. This represents a 0.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hadi Partovi acquired 1,358 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, August 13th. The stock was acquired at an average cost of $740.00 per share, for a total transaction of $1,004,920.00. Following the purchase, the director owned 237,938 shares of the company’s stock, valued at $176,074,120. The trade was a 0.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 44,865 shares of company stock valued at $34,362,833. 4.40% of the stock is owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.